Additionally, the Sycn protein is significantly increased in plasma from pancreatic cancer patients by enzyme-linked immunosorbent assay (ELISA) and integrated proteomic profiling of cell lines and pancreatic secretions [38]. This evidence concerns the gene SYCN and pancreatic neoplasm.